A bispecific mAb that neutralizes both IL‐4 and IL‐13 for the treatment of asthma, based on the IgG4 antibody Lebrikizumab, generates higher titers than its predecessor, an IgG1 bispecific antibody 135. Here, IL13 is linked to asthma.